Articles

The lack of transparency in the pharmaceutical industry further exacerbates the challenges faced by consumers. 

Navigating the Complexities of Prescription Drug Pricing: Affordable Solutions Are Available to Self-Insured Plan Sponsors

Tagrisso (osimertinib) approved for use in combination with platinum-based chemotherapy in adults with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R mutations.

FDA Approves Tagrisso With Chemotherapy for EGFR-Mutated Advanced Lung Cancer

Iovance’s Amtagvi (lifileucel) gains FDA accelerated approval for adults with unresectable or metastatic melanoma.

FDA Approves First One-Time, Individualized T Cell Therapy for a Solid Tumor

The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle. 

ValGenesis, RxCloud Collaborate on Tackling Compliance and Quality Assurance Challenges

The new seals include sustainable film material containing recyclate content of up to 90%.

Schreiner MediPharm Unveils New Closure Seals for Pharma Packaging

Xolair (omalizumab) was previously granted FDA Priority Review status and Breakthrough Therapy Designation to prevent severe allergic reactions after accidental exposure to one or more foods in people with allergies. 

FDA Approves First Treatment for Multiple Food Allergies in Adults, Children 

Strategic and proactive thinking are vital in providing supply chain leaders with an opportunity to shift their focus to a more holistic, value-centered approach. 

Three Areas to Drive Supply Chain Value 

Tepmetko (tepotinib), an oral MET inhibitor, was granted accelerated approval in 2021 for metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.

FDA Grants Full Approval to Tepmetko for Metastatic NSCLC Subtype 

Personalized medicine approaches, informed by predictive modeling, could optimize treatment outcomes and reduce patient burden and costs.

Artificial Intelligence May Accelerate Time to Determine Response to Treatment

The financial commitment features construction of new warehouses in Pennsylvania and North Carolina. 

News